2018
Costs of relapsed diffuse large B-cell lymphoma among Medicare patients
Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leukemia & Lymphoma 2018, 59: 2880-2887. PMID: 29936866, DOI: 10.1080/10428194.2018.1459613.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCost of IllnessFemaleHealth Care CostsHospitalizationHumansInsurance Claim ReviewLymphoma, Large B-Cell, DiffuseMaleMedicareNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeUnited StatesConceptsDiffuse large B-cell lymphomaHealth care costsLarge B-cell lymphomaFirst-line treatmentB-cell lymphomaCare costsHealth care expendituresCare expendituresHigher health care costsOffice visit costsSecond-line therapyFirst-line therapyHigher medical costsLikelihood of relapseRelapsed cohortMedicare patientsMedicare claimsMedical costsVisit costsPropensity scoreOlder adultsPatientsLymphomaTherapyTreatment
2016
Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database
Mato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Fanning M, Doshi J, Huntington S. Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4790. DOI: 10.1182/blood.v128.22.4790.4790.Peer-Reviewed Original ResearchSecond-line treatmentChronic lymphocytic leukemiaSecond-line cohortSecond-line therapyOverall survivalLine treatmentInitial therapyClinical trialsLine therapyInitial treatmentCLL treatmentSurvival outcomesCLL patientsOlder adultsNovel agentsCLL outcomeLymphocytic leukemiaMedicare feeCommon second-line treatmentReal-world survival outcomesRecent landmark clinical trialsRelapsed chronic lymphocytic leukemiaMultivariate Cox regression modelingSecond lineAdvisory Committee